B7–H3 regulates osteoclast differentiation via type I interferon-dependent IDO induction [PDF]
Cell Death and Disease, 2021 While their function, as immune checkpoint molecules, is well known, B7-family proteins also function as regulatory molecules in bone remodeling. B7–H3 is a receptor ligand of the B7 family that functions primarily as a negative immune checkpoint.
Younseo Oh +6 more
doaj +2 more sources
Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer [PDF]
BMC Cancer, 2009 Background Costimulatory signaling has been implicated as a potential regulator of antitumor immunity in various human cancers. In contrast to the negative prognostic value of aberrant B7-H1 expression by pancreatic cancer cells, the role of B7-H3 is ...
Kleeff Jörg +7 more
doaj +4 more sources
B7-H3 is widely expressed in soft tissue sarcomas [PDF]
BMC CancerPurpose Targeted therapy development in soft tissue sarcoma (STS) has been burdened by the heterogeneity of this group of rare tumors. B7 homolog 3 protein (B7-H3) is a molecule in the same family as programmed death-ligand 1 (PD-L1).
Meghan M. Lynch +13 more
doaj +4 more sources
Design and Preclinical Validation of an Anti-B7-H3-Specific Radiotracer: A Non-Invasive Imaging Tool to Guide B7-H3-Targeted Therapies [PDF]
PharmaceuticalsBackground: B7-H3, an immunoregulatory protein of the B7 family, has been associated with both anti-cancer immunity and tumor promotion, with its expression commonly correlated with poor prognosis.
Cyprine Neba Funeh +5 more
doaj +2 more sources
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape [PDF]
Journal of Hematology & OncologyBackground CAR T cell therapy targeting BCMA has shown remarkable efficacy in multiple myeloma (MM), but relapses occur due to T cell exhaustion and the emergence of BCMA-negative subpopulations.
Arne Van der Vreken +21 more
doaj +2 more sources
Research progress of B7-H3 in malignant tumors. [PDF]
Front ImmunolB7 homolog 3 (B7-H3, also known as CD276) is a novel member of the B7 immune protein family. There is a marked difference in the expression and distribution of B7-H3 protein and mRNA between normal and tumor tissues, with widespread expression in tumor ...
Zhao S, Zhang H, Shang G.
europepmc +3 more sources
Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature [PDF]
Frontiers in OncologyB7-H3 (CD276), an immune checkpoint molecule, is overexpressed in various types of cancer and their tumor vasculature, demonstrating significant associations with adverse clinical outcomes.
Shuo Wu +4 more
doaj +3 more sources
High B7-H3 protein expression in Medulloblastoma is associated with metastasis and unfavorable patient outcomes [PDF]
Diagnostic PathologyBackground Medulloblastoma (MB) is the most common malignant brain tumor in children. Although the 5-year survival rate is approximately 70–80%, the current standard treatment results in severe and long-term side effects.
Patrícia Fontão +8 more
doaj +2 more sources
Gastric carcinomas with stromal b7-h3 expression have lower intratumoural cd8+ t cell density [PDF]
, 2021 Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.CD8+ T cells are the main effector cells of anti-cancer immune response that can be regulated by various costimulatory and coinhibitory molecules, including members of the B7 ...
Behrens, Hans Michael +4 more
core +1 more source
Immune Checkpoint B7-H3 Is a Therapeutic Vulnerability in Prostate Cancer Harboring Pten and TP53 Deficiencies [PDF]
, 2023 Checkpoint immunotherapy has yielded meaningful responses across many cancers but has shown modest efficacy in advanced prostate cancer. B7 homolog 3 protein (B7-H3/CD276) is an immune checkpoint molecule and has emerged as a promising therapeutic target.
Aparicio, Ana +13 more
core +2 more sources